United States 
Canada
EU
UKWe’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: Muscular Dystrophy Association (MDA)
Date: March 19 - 22, 2023
Expanded Access to Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Updates and Initial Learnings
Lead Author: Sandy Morris, BA, BS, MBA & Philip Green, BS (Presenter)
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Independent Expert Review of Cardiac Adverse Events and Electrocardiographic Abnormalities and Parameters in a Phase 2 Trial of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (CENTAUR)
Lead Author: Shide Badri, MD, MPH
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Update on an International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Cerebrospinal Fluid Biomarker Effects and Target Engagement From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease: Results From the PEGASUS Trial
Lead Author: Steven E. Arnold, MD
Published: Clinical Trials on Alzheimer’s Disease (CTAD)
Date: December 3, 2022
Development of AMX0114, an Antisense Oligonucleotide Targeting Calpain-2
Lead Author: Mathias Leinders, PhD
Published: Society for Neuroscience (SfN)
Date: November 12 - 16, 2022
Real-World Strategies to Enhance the Palatability of Coformulated Sodium Phenylbutyrate and Taurursodiol for the Treatment of Amyotrophic Lateral Sclerosis
Lead Author: Nicole Shuckett, RD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 2, 2022
Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 1, 2022
Reduced Plasma Concentration of the Neuroinflammation Biomarker Chitinase-3-Like Protein (CHI3L1/YKL-40) in the CENTAUR Trial
Lead Author: Robert Bowser, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: November 1, 2022
International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Congress on Neuromuscular Diseases (ICNMD)
Date: July 9, 2022